Partnership Institut Curie & PEP-Therapy announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors10/05/2021
Innovation Aglaia Therapeutics: a new start-up from Institut Curie & Gustave Roussy raises €4M to fight resistance to targeted therapies09/24/2021
Innovation PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate PEP-01007/19/2021
Partnership Metastatic breast cancer: Institut Curie structures a specific patient circuit, with the institutional support of Pfizer06/28/2021
Innovation Institut Curie applauds the €75 million fundraising achieved by its spin-off Mnemo Therapeutics06/14/2021
Partnership “Flash" radiotherapy: another step towards clinical applications for Institut Curie and SIT 05/03/2021
Innovation PEP-Therapy raises €2.75 million in Series A to advance its lead candidate into the clinic04/26/2021
